# Rhythm Pharmaceuticals gains Japan approval for IMCIVREE in hypothalamic obesity

- Link: https://www.directorstalkinterviews.com/rhythm-pharmaceuticals-gains-japan-approval-for-imcivree-in-hypothalamic-obesity/4121261295
- Published: 2026-08-27T12:10:00+01:00
- Author: Amilia Stone

Rhythm Pharmaceuticals has received approval from Japan’s Ministry of Health, Labour
and Welfare for IMCIVREE, or setmelanotide, to treat acquired hypothalamic obesity.

IMCIVREE is the first treatment approved in the country specifically for acquired
hypothalamic obesity.

Rhythm expects to make IMCIVREE available in Japan before the end of 2026, subject
to final pricing arrangements. This means the regulatory risk has been reduced, 
while pricing and commercial execution now become the main factors determining how
quickly the Japanese opportunity can begin contributing to the business.

Rhythm estimates that around 5,000 to 8,000 people in Japan are living with acquired
hypothalamic obesity.

Acquired hypothalamic obesity can occur following damage to the hypothalamus, including
after surgery or treatment for certain tumours. The condition can lead to rapid 
and difficult-to-control weight gain because the hypothalamus plays a central role
in regulating hunger, energy use and body weight.

IMCIVREE is designed to act on the melanocortin-4 receptor pathway, known as the
MC4R pathway. Rhythm has built its development strategy around rare forms of obesity
where disruption of this pathway contributes to severe hunger and weight gain.

_**Biotech Growth Trust plc** (LON:BIOG) seeks capital appreciation through investment
in the worldwide biotechnology industry. The Company and the Company’s Portfolio
Manager believe that there is a high congruence between companies that seek to act
responsibly and those that succeed in building long-term shareholder value. _

Share on:
